尼妥珠单抗靶向治疗鼻咽癌的有效性及安全性与耐受性

Study on the Efficacy,Safety and Tolerability of Nituzumab Patients with Nasopharyngeal Carcinoma

目的探讨尼妥珠单抗靶向治疗鼻咽癌的有效性及安全性与耐受性。方法选取80例鼻咽癌患者,采用随机数字表法分为2组,每组各40例。2组均行3周期TPF方案诱导化疗,对照组在放疗开始时静脉滴注顺铂,观察组于放疗前1周静脉滴注尼妥珠单抗。3周为1个疗程,2组均治疗2个疗程。比较2组临床疗效、不良反应、耐受性以及血清血管内皮生长因子(VEGF)和转化生长因子(TGF-β1)水平。结果观察组临床总有效率(92.50%)高于对照组(72.50%),发热、消化道反应、心电图异常、骨髓抑制等不良反应发生率低于对照组。观察组治疗后VEGF水平为(190.12±20.63)pg/ml、TGF-β1水平为(19.54±2.06)μg/ml,低于对照组的(213.46±28.34)pg/ml、(36.23±3.78)μg/ml。对照组治疗中断率(25.00%)高于观察组(2.50%),差异有统计学意义(P<0.05)。结论尼妥珠单抗靶向治疗鼻咽癌效果较佳,能抑制肿瘤血管形成,患者耐受性较好,不良反应少,安全可靠。

Objective To investigate the efficacy,safety and tolerability of nituzumab targeted therapy in patients with nasopharyngeal carcinoma.Methods 80 patients with nasopharyngeal carcinoma,using the random number table method,were divided into 2 groups.Each with 40 cases.Both groups underwent 3-cycle TPF regimen-induced chemotherapy,The control group received cisplatin intravenously at the beginning of radiotherapy,The observation group was intravenous drip of rituximab 1 week before radiotherapy.Three weeks as a course of treatment,Both groups were treated for 2 courses.Comparison of clinical efficacy,adverse reactions,tolerance and serum vascular endothelial growth factor(VEGF)and TGF(TGF-β1)levels.Results The total clinical effective rate(92.50%)in the observation group was higher than that in the control group(72.50%),The incidence of fever,digestive tract reaction,abnormal electrocardiogram,bone marrow suppression and other adverse reactions was lower than that of the control group,Observation group VEGF(190.12±20.63)pg/ml、TGF-β1(19.54VEGF(190.12±2.06))μg/ml,after treatment Less than the control group(213.46±28.34)pg/ml、(36.23±3.78)μg/ml,Treatment interruption rate(25%)in control group Compared with the control group(2.50%),the difference was statistically significant(P<0.05).Conclusion Nittozumab is effective in clinical treatment of nasopharyngeal carcinoma,which can inhibit tumor angiogenesis,tolerance,less adverse reactions,safety and reliability.